News | 24 March 2025
Briefs: Alembic Pharmaceuticals and Shelter Pharma
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
The products will be manufactured in Goa India and marketed & distributed in Australian markets
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare
First-of-its-kind active cosmetic ingredient directly activates the oxytocin receptor, mimicking the dermatological effects of being in love
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products
Nipaguard SCE Vita delivers comprehensive antimicrobial protection for personal care formulations
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
Subscribe To Our Newsletter & Stay Updated
_195_291.jpg)